Inappropriate Antibiotic Use Increased During Pandemic - Medscape

LISBON, Portugal — During the pandemic, critical and acute care hospitals with medium and high rates of antimicrobial resistance (AMR) showed significant increases in antibiotic prescriptions and longer durations of antibiotic treatment among all hospital admissions, and also in those patients who were bacterial culture-negative, according to a large US-based study.

The analysis across 271 US hospitals also showed that AMR rates were significantly higher for pathogens during the pandemic period compared with the prepandemic period in patients who were tested for SARS-CoV-2, and highest in SARS-CoV-2 positive patients.

More than a third of SARS-CoV-2 positive patients who were prescribed antibiotics were bacterial culture-negative.

Findings of the study were presented by Vikas Gupta, PharmD, director of Medical Affairs at medical technology firm Becton, Dickinson and Company, at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). He conducted the study jointly with Karri Bauer, PharmD, from Merck Sharp & Dohme, Kenilworth, New Jersey, and colleagues.

"There are differences in AMR that go beyond COVID-positive admissions," Gupta told Medscape Medical News. "There is opportunity for improvement especially with those hospitalized patients who had a negative culture result, or no culture collected.

"We found a higher percentage of COVID-positive admissions that were prescribed antibacterial therapy even in those having [tested negative for bacteria] or no culture result," said Gupta. "Our data also shows that the percentage of admissions with duration of antibacterial therapy over 3 days was significantly higher in COVID-positive but culture-negative/no culture patients compared to other groups evaluated."

Of all admissions prescribed antibiotics during the pandemic, 57.8% of SARS-CoV-2 positive patients were prescribed antibiotics whereas 88.1% of SARS-CoV-2-positive admissions were bacterial culture-negative/no culture. Overall, prepandemic, 35% of admissions were prescribed antibiotics.

Duration of antibiotic therapy in the prepandemic era was an average of 3.5 days compared with an average of 3.8 days overall in the pandemic and 5.7 days in patients tested positive for SARS-CoV 2. Similarly, the percentage of patients who were bacterial culture-negative or had no culture and received antibiotic therapy for more than 72 hours was 17.6% in the pre-pandemic era compared with 19.2% overall in the pandemic era, and 41.1% in patients who tested positive for COVID-19.  

Gupta and Bauer wanted to look at all patients admitted to hospitals segmented by SARS-CoV-2 positive, negative, and not tested, to get a sense of how much antibiotic use there was and how long patients were on antibiotics. "We ultimately want to optimize and not overuse antibiotics and prescribe them for right period of time," said Gupta.

"To date, there has been no conclusive evidence about the suggestion that the pandemic has led to increased AMR rates, so we aimed to evaluate the pandemic's impact on AMR and antibiotic use across US hospitals," he explained.

The multicenter, retrospective cohort analysis made use of BD's infection surveillance platform (BD HealthSight™ Infection Advisor with MedMined™ Insights) and was conducted across 271 US critical access/acute care facilities, representing approximately 10%-13% of US hospital admissions. It included all hospitalized patients with more than 1 day of in-patient admission. Patients were considered SARS-CoV-2-positive by PCR test or antigen test either 7 days or less prior to or within 14 days of admission.

Patients were categorized as hospitalized during the "prepandemic" period (July 1, 2019 through February 29, 2020) and the "pandemic" period (March 1, 2020 through October 30, 2021) and were stratified based on their SARS-CoV-2 result. 

Investigators included all hospital admissions with an AMR event (first positive culture for select gram-negative or gram-positive pathogens that were reported as nonsusceptible across blood, urine, respiratory, intra-abdominal, skin/wound, and other sources).

The investigators calculated AMR rates at the patient-admission level and defined per 100 admissions. Also, they further evaluated AMR rates based on community-onset (defined as culture collected ≤ 2 days from admission) or hospital-onset (> 2 days from admission). Finally, AMR rates were determined according to whether they related to prepandemic or pandemic periods. 

Hospitals were also categorized according to their AMR rates as low (< 25%), medium (25%-75%), and high (> 75%). 

Overall AMR rates were lower in the pandemic period compared with the prepandemic period. However, reported Gupta, for hospital-onset pathogens specifically, AMR rates were significantly higher overall in the pandemic period and mostly driven by admissions tested for SARS-CoV-2 (whether positive or negative).

Hospitals with high AMR rates also tended to have more SARS-CoV-2 positive admissions (6.1% in high AMR hospitals vs 3% in low AMR hospitals). The highest antibiotic prescribing rates and highest duration of antibiotic use was also seen in those hospitals with highest AMR rates. 

Of the SARS-CoV-2 patients who were bacterial culture-negative/no culture and were prescribed antibiotics, 36.5% were in hospitals with a high AMR rate. "Roughly one third of patients without culture evidence of a bacterial infection were prescribed antibiotics in hospitals with a high AMR rate," said Gupta.

The researchers wanted to tease out whether hospitals with high, moderate, or low AMR rates look different with respect to antibiotic prescribing patterns. During the pandemic period, they found that hospitals with high and medium AMR rates experienced significant increases in antibiotic prescriptions and longer durations. Prepandemic, the overall hospital-onset AMR rate was 0.8 per 100 admissions, whereas during the pandemic this rose to 1.4 per 100 admissions in high AMR hospitals and dropped to 0.4 in low AMR hospitals.

SARS-CoV-2-positive admission rates were higher in facilities with medium (5.6%) and high AMR (6.1%) rates than those with low (3%) AMR rates. "We found that those with medium and high AMR rates were more likely to have COVID-positive admissions than facilities with low AMR rates," Gupta said. "It appears as if COVID is contributing to AMR in the facilities."

Asked for independent comment, Jason C. Gallagher, PharmD, BCPS, clinical professor at Temple University School of Pharmacy in Philadelphia, told Medscape, "It is not surprising that there was more antimicrobial resistance in patients with COVID than those without. Even though antibiotics do not work for COVID, they are often prescribed, and antibiotic use is a major risk factor for antimicrobial resistance. This is likely because clinicians are sometimes concerned about coinfections with bacteria (which are rare) and because hospitalized patients with severe COVID can acquire other infections as they are treated."

Antibiotic Stewardship Programs

Antibiotic stewardship programs have been highly stressed during the pandemic, so the researchers hope their data support the need for better antibiotic stewardship practices during pandemic surges when control is more challenging.

Gupta explained that they were seeing interesting associations that can inform antimicrobial stewardship programs and teams. "We are not trying to imply causality," he stressed.

It is a common practice for stewardship teams to evaluate the need for continuation of antibiotic therapy at 3 days, especially in patients who are culture negative or did not have a culture collected.

"Antibiotic time-out at 3 days is a recommended practice to evaluate for continuing antibiotic therapy based on the patient's condition and culture results," he said. "This is what made our study unique because we wanted to look at what percentage of admissions were prescribed antibiotics beyond 3 days and compare to the prepandemic period."

Session moderator Evangelos J. Giamarellos-Bourboulis, MD, PhD, an assistant professor of internal medicine and infectious diseases, University of Athens, Greece, thanked Gupta for his "eloquent presentation" and sought to clarify whether the data "refer to antimicrobial use that was empirical or whether use was in hospitals with high AMR rates, or whether the approach was driven through microbiology?"

Gupta replied that this was why they evaluated the negative-culture and no-culture patients. "We wanted to get a measure of antibacterial use in this population too," he said. "Definitely, there is empirical therapy as well as definitive therapy, but I think the negative and no-culture group provide a reference point where we see similar signals and trends to that of the overall population."

An audience member also addressed a question to Gupta: "Did you look at the patient population, because in many cases, during COVID, these patients may have been more severe than in the prepandemic period?"

Gupta replied: "In our manuscript we've done an analysis where we adjusted for patient-level facility and regional-level factors. There are definitely differences in the patient populations but overall, these are pretty sick patients when we look at the level of severity overall."

Gupta is an employee of and a shareholder in Becton, Dickinson and Company. Bauer is an employee of and a shareholder in Merck & Co. Inc. Gallagher consults for many pharmaceutical companies including Merck.

Giamarellos-Bourboulis disclosed honoraria (paid to the University of Athens) from Abbott CH, Brahms Thermo Fisher GMBH Germany, GlaxoSmithKline, and Sobi; serving as a consultant for Abbott CH, Fab'nTech, InflaRx GmbH, UCB, Sobi, and Xbiotech Inc; research grants (paid to the Hellenic Institute for the Study of Sepsis) from Abbott CH, BioMerieux France, Johnson & Johnson, MSD, Sobi, Thermo Fisher Brahms GmbH; and EU research funding: Horizon 2020 ITN European Sepsis Academy (granted to the University of Athens); Horizon 2020 ImmunoSep and RISinCOVID (granted to the Hellenic Institute for the Study of Sepsis); Horizon Health EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis).

32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID): Abstract 4960. Presented April 25, 2022.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn